Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02858245 · ClinicalTrials.gov registry record
A Feasibility Registry of Actigraphy Monitoring in Degenerative Mitral Regurgitation Subjects Receiving the MitraClip® Device
A clinical trial, sponsored by Abbott Medical Devices.
- Terminated
- Registry status
- 30
- Enrollment target
NCT02858245: Clinical Trial study, sponsored by Abbott Medical Devices.
NCT02858245 is a clinical trial that was terminated before completion, run by Abbott Medical Devices. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02858245 was terminated before completion, sponsored by Abbott Medical Devices.
- TERMINATED
- Registry status
- 30 participants
- Enrollment target
Study Summary
A prospective, open-label, and multi-centered feasibility registry.
Primary Outcome
Phillips Actiwatch Spectrum PRO is the device being used to capture the primary outcome measure
Interventions
- OTHER No intervention - registry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-11 |
| Est. Completion | 2017-12 |
Why NCT02858245 stopped before completion
NCT02858245 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which No intervention - registry is the first listed.
NCT02858245 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02858245 about?
NCT02858245 is a clinical study titled "A Feasibility Registry of Actigraphy Monitoring in Degenerative Mitral Regurgitation Subjects Receiving the MitraClip® Device". A prospective, open-label, and multi-centered feasibility registry.
What is the current status of trial NCT02858245?
This trial is currently terminated. The enrollment target is 30 participants. The study started on 2016-11. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02858245?
The interventions under investigation include: No intervention - registry (OTHER).
Who is sponsoring clinical trial NCT02858245?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia